LSTA
What one share of Lisata Therapeutics holds
Pharmaceutical Preparations
Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other serious diseases.
Lisata Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$1.64 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.38 |
| Cash and investments | $1.15 |
| Book value | $0.90 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$74.81 | $2.52 | −$56.73 | — | $8.93 |
| 2017 | — | $38.43 | $0.23 | −$35.14 | — | $79.88 |
| 2018 | — | −$25.03 | $0.21 | −$31.15 | — | $57.36 |
| 2019 | — | −$28.13 | $0.00 | −$27.43 | — | $29.69 |
| 2020 | — | −$7.92 | $0.02 | −$8.59 | — | $25.15 |
| 2021 | — | −$7.45 | $0.02 | −$6.05 | — | $23.14 |
| 2022 | — | −$10.47 | $0.06 | −$4.14 | — | $8.46 |
| 2023 | — | −$2.58 | $0.00 | −$2.48 | — | $5.91 |
| 2024 | $0.12 | −$2.40 | $0.00 | −$2.32 | — | $3.52 |
| 2025 | $0.02 | −$1.91 | $0.00 | −$1.84 | — | $1.68 |